Operational Update, Placing and TVR

Genip

04/12/2025 07:00

RNS Number : 1548K

GenIP PLC

04 December 2025

 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF REGULATION (EU) 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EU (WITHDRAWAL) ACT 2018 ("MAR"). IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN MAR) WERE TAKEN IN RESPECT OF THE PLACING WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED IN MAR), AS PERMITTED BY MAR. THIS INSIDE INFORMATION IS SET OUT IN THIS ANNOUNCEMENT. THEREFORE, THOSE PERSONS THAT RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION RELATING TO THE COMPANY AND ITS SECURITIES.

4 December 2025

GenIP Plc

("GenIP" or the "Company")

Operational Update, Placing to Accelerate Growth and Total Voting Rights

GenIP Plc is pleased to announce that it has raised £300,000 (before expenses) through a placing of 3,000,000 new ordinary shares of £0.00425 each (the "Ordinary Shares") in the Company (the "Placing Shares") at an issue price of 10p per Placing Share (the "Placing") to accelerate platform automation and global commercial expansion.

 

Operational Update

GenIP has moved from an early-stage company traded on AIM to a revenue generating partner for universities, corporates and investors in innovation triage and commercialisation.

Key achievements:

·    Expanded the product suite beyond single technology evaluations to portfolio and macro level tools for budget holders across universities, corporates and grant institutions.

·    Established recurring client relationships with universities across six continents - validating the commercial value of GenIP's products.

·    Secured new contracts in new territories - $350k in Saudi Arabia; $65k in Singapore.

·    Formed strategic LATAM partnerships providing direct access to more than 500 innovation focused institutions - Brazil technology and science park; Brazil new venture studio; a Green Tech Platform, led by a University in Chile, where GenIP is the designated technology transfer supplier.

Strategic Investment

This Placing is a strategic investment focused on capturing market opportunities and driving automation into new products that will deliver enhanced gross margins.

Together, this will establish a technical foundation for future growth and scale.

Use of Proceeds: High-Margin Automation & Scalability

The net proceeds of the Placing will be used in two ways:

For Platform automation and integration leading to margin growth (Primary Focus): (67%)

●    Embed the new high value products (Invention Validator, Invention Prioritizer, and Competitive Intelligence Reports) into the core Invention Evaluator platform.

●   Manual processes will be reduced through automation and embedding, leading to higher gross margins and scalability.

●    These products are already commercially adopted in Saudi Arabia, UK, and South Africa.

For Targeted Commercial Conversion in Asia and LATAM (Focused Support): (33%)

●   Technology transfer in Asia and LATAM is less developed than in Europe and US markets, requiring greater dedicated sales and commercial resource to close deals. These territories have substantial portfolios of innovations to be evaluated and managed, creating significant opportunities for GenIP.

●   GenIP has already secured significant contracts in Asia and LATAM and additional sales resource is now required to build on existing contracts and partnerships to secure renewal business and cross referrals.

Melissa Cruz, GenIP's CEO, commented:

"This investment enables the technical integration of our new, high-value products into a single, automated platform. This directly supports margin growth and establishes the essential foundation for scalable expansion."

Placing

The Company has raised £300,000 (before expenses) through the issue of 3,000,000 Placing Shares at an issue price of 10p per Placing Share, which represents a discount of approximately 46% to the closing mid-price of 18.5p as at the close of business on 3 December 2025, being the last practicable date prior to publication of this announcement. The Placing Shares represent approximately 17% of the Company's existing issued share capital. Each Placing Share will have one warrant attached, exercisable at 20p for a period of two years from the Admission of the Placing Shares to trading on AIM. The Placing was undertaken by the Company's Broker, AlbR Capital Limited.    

Broker Warrants

As consideration for its services in connection with the Placing, the Company will issue the Broker with warrants over such number of Ordinary Shares as is equal to 5 per cent. of the Placing Shares (each a "Broker Warrant"). Each Broker Warrant will be exercisable at 10p up until three years from the date of Admission.

Concert Party interest

The Concert Party (as defined in the Admission Document published on 26 September 2024), is currently interested in aggregate in 71.30% of the existing issued share capital reducing to 60.88% in the enlarged issued share capital on Admission. As the members of the Concert Party therefore currently hold and will continue to hold on Admission more than 50 per cent. of the voting rights in the Company, for so long as the Concert Party's aggregate interest remains above 50 per cent. of the voting rights in the Company, it will generally be able to increase its shareholding without incurring any obligation on any member of the Concert Party under Rule 9 of the Takeover Code to make a general offer to Shareholders (subject to the considerations in Note 4 on Rule 9.1 of the Takeover Code).

Application for Admission

Application has been made for the Placing Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will take place and that trading will commence on AIM at 8.00 a.m. on or around 18 December 2025. Once issued, the Placing Shares will rank pari passu with the Company's existing Ordinary Shares.

Total Voting Rights

Following Admission of the Placing Shares, the enlarged issued share capital of the Company will comprise 20,517,461 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Consequently, 20,517,461 is the figure which may be used by shareholders from Admission as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

ENDS

 

For further information regarding GenIP, please visit www.genip.ai, or contact:

 

GenIP Plc
Melissa Cruz, CEO
Via Redchurch Communications
Beaumont Cornish Limited (Nominated Adviser)
Roland Cornish / Asia Szusciak / Andrew Price
Tel: +44 (0) 20 7628 3396
AlbR Capital Limited (Broker)
Colin Rowbury
Jon Belliss
Tel: +44 (0)20 7399 9427
cr@albrcapital.com
Jb@albrcapital.com
Redchurch Communications (Financial PR)
John Casey
genip@weareredchurch.com

 

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

Notes to Editors

 

About GenIP

 

GenIP is a next-generation company at the intersection of generative AI and innovation strategy. We empower corporates, venture funds, and research institutions to evaluate, commercialise, and scale breakthrough technologies. By combining proprietary GenAI algorithms with expert human analysis, GenIP delivers decision-grade insights and talent solutions that accelerate innovation outcomes.

 

Service Offerings

 

GenIP operates through two synergistic service lines:

 

 

Service
Description
Value Proposition
Invention Intelligence Product Suite
AI-powered market intelligence reports assessing the commercial potential of emerging technologies.
Invention Evaluator
Invention Prioritizer
Invention Validator
Competitive Intelligence Reports
Enables faster, evidence-based decisions on R&D prioritisation, investment, and IP strategy
Talent and Executive Search Services
Executive search platform using machine learning and NLP to match innovation-driven organisations with commercialisation-ready leadership
De-risks scaling by aligning technical vision with proven executive capability

 

Together, these services form a unified GenAI-enabled platform for innovation triage and commercialisation.

 

Vision & Strategy

 

GenIP aims to become the global leader in generative AI analytics for innovation commercialisation. Our strategy is anchored in three growth pillars:

 

●     Organic Expansion

Scale Invention Intelligence and Recruitment Services through targeted outreach to corporates, VCs, and research institutions.

●     Service Deepening

Enhance functionality and margin by expanding GenAI capabilities within both service lines-unlocking new use cases and customer segments.

●     Strategic Acquisitions

Pursue bolt-on acquisitions of complementary GenAI services with validated market traction to broaden our offering and accelerate growth.

 

Forward looking statements

 

Certain statements contained in this announcement constitute forward-looking statements. When used in this announcement, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "seek", "propose", "estimate", "expect", and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial position, liquidity, prospects, growth, strategies and expectations of the industry in which the Company operates.

 

Such statements reflect the Company's current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to materially differ from those described in this announcement Should one or more of these risks or uncertainties materialise, or should assumptions underlying forward-looking statements prove incorrect, actual results may differ materially from those described in this announcement as "intended", "planned", "anticipated", "believed", "proposed", "estimated" or "expected".

 

For the avoidance of doubt, the contents of the Company's website and any hyperlinks accessible from the Company's website are not incorporated by reference into, and do not form part of, this announcement and investors should not rely on them.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
IOEFLFITFILVIIE